<DOC>
	<DOCNO>NCT02436993</DOCNO>
	<brief_summary>The purpose phase II study efficacy toxicity carboplatin paclitaxel pertuzumab trastuzumab HER2 positive carboplatin paclitaxel bevacizumab HER2 negative neoadjuvant set treatment breast cancer .</brief_summary>
	<brief_title>Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab Bevacizumab</brief_title>
	<detailed_description>OBJECTIVES There two study component , 1 ) evaluate treatment response toxicity protocol , 2 ) investigate role Magnetic Resonance Imaging ( MRI ) monitor predict final pathological response . Objectives treatment study component : 1.1 To estimate 2-year progression-free survival patient breast cancer tumor 1 cm and/or clinically detect lymph node treat neoadjuvant weekly Carboplatin Paclitaxel combine Trastuzumab + Pertuzumab HER2-positive disease Bevacizumab HER2-negative disease . 1.2 To measure microscopic complete pathological response ( pCR ) rate define ypT0 Ductal carcinoma situ ( DCis ) tumor patient treat regimen neoadjuvant setting . 1.3 To assess complete clinical response ( cCR ) rate treatment physical exam imaging test ( ultrasonography , mammography , magnetic resonance imaging ) clinical objective response rate ( Response Evaluation Criteria In Solid Tumors ( RECIST ) ) 1.4 To determine toxicity regimen . 1.5 To determine treatment adherence deliver dose intensity regimen . 1.6 To assess correlation pCR cCR . 1.7 To determine rate breast conservation follow neoadjuvant therapy . 1.8 Determine treatment efficacy accord subgroup define accord stage receptor status . Objectives MRI response monitoring study component : 1.9 Develop quantitative analysis method obtain pre-treatment tumor characteristic breast cancer ( include morphological enhancement kinetic parameter ) select optimal set feature use logistic regression analysis Artificial Neural Network ( ANN ) predict pathologic complete remission ( pCR ) HER2-positive negative arm . 1.10 Investigate whether early response pattern tumor ( change percent tumor size tumor characteristic parameter ) use predict pathologic complete remission ( pCR ) HER2 positive negative arm . 1.11 Investigate whether combine pre-treatment characteristic parameter early response pattern achieve high AUC ( area Receiver Operating Characteristic ( ROC ) curve ) prediction pCR base pre-treatment MRI characteristic tumor response pattern alone .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically proven unilateral bilateral primary breast carcinoma . ( In case bilateral cancer , investigator decide prospectively side evaluated primary endpoint . ) Tumor size clinically least 1 cm great diameter ( palpable imaging ) and/or involve lymph node . In case inflammatory disease , extent inflammation may measurable lesion . Documentation inflammatory breast cancer Inflammatory breast cancer ? Woman age &gt; = 18 Performance status 02 Eastern Cooperative Oncology Group ( ECOG ) criterion Known HER2 status Normal cardiac function must document within 90 day prior registration . Result ejection fraction must normal limit institution . Date Echo multigated acquisition ( MUGA ) ( within 90 day ) Staging workup prior registration Date physical examination ( within 90 day ) Date bilateral mammogram ( within 90 day ) Date breast ultrasound ( within 30 day ) Date MRI breast ( within 30 day ) Chest Xray ( within 90 day ) Other test clinically indicate Laboratory requirement : Hematology : Absolute Neutrophil Count ( ANC ) ≥ 1,500/μl Platelets ≥ 100,000/μl Hepatic Function Total Bilirubin &lt; 1x upper limit normal ( ULN ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2x ULN Renal Function Creatinine &lt; 1.5x ULN Proteinuria Urine dipstick proteinuria &lt; 2+ . Patients discover ≥2+ proteinuria dipstick undergo 24hour urine collection demonstrate ≤ 1g protein 24 hour . Negative pregnancy test woman childbearing potential within 14 day prior registration . All patient must inform investigational nature study must sign and\give write informed consent accordance institutional federal guideline . Evidence distant metastasis Known suspect congestive heart failure , angina pectoris require antianginal medication , clinically significant cardiac condition . Pregnant nursing woman may participate due possibility harm fetus nursing infant treatment regimen . Women childbearing potential may participate unless agree use adequate contraceptive method throughout study treatment one month completion treatment . Male patient Preexisting peripheral neuropathy severity grade ≥ 2 ( limit instrumental activity daily live ) . Incomplete wound heal . Active significant bleed Known allergy , hypersensitivity prior infusion reaction one therapy incorporate treatment protocol . Bone marrow depression hematologic parameter range would increase risk severe bleeding . Exclusion criterion participate MRI monitoring substudy : Subjects eligible participate MRI response monitoring substudy , : Implanted prosthetic heart valve , pacemaker , neurostimulation device , surgical clip ( hemostatic clip ) metallic implant . Engaged occupation activity may cause accidental lodge ferromagnetic material , imbed metal fragment military activity . Received orthodontic work involve ferromagnetic material . Claustrophobia ( fear enclose space ) . Previously allergic response MR contrast agent ( gadolinium ) . Known history severe renal insufficiency , asthma , allergic condition , sickle cell anemia , chronic hemolytic anemia , gastrointestinal disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Neoadjuvant Treatment</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Pertuzumab</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>